XM không cung cấp dịch vụ cho cư dân của Mỹ.
G
G

Galapagos


Tin tức

Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary

Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary Galapagos NV GLPG.AS reported a quarterly adjusted loss of 77 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 39 cents. The mean expectation of two analysts for the quarter was for a loss of 49 cents per share.
G

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 30 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. VIVENDI VIV.PA : Paris-based investment fund CIAM said on Tuesday it would appeal to France's financial watchdog AMF to ensure shareholder rights are respected in Vivendi's plan to split up, urging a public offer be launched for Vivendi shares.
E
G
V
F
N
U

Galapagos NV <GLPG.OQ> expected to post a loss of 27 cents a share - Earnings Preview

Galapagos NV expected to post a loss of 27 cents a share - Earnings Preview Galapagos NV GLPG.OQ , GLPG.O is expected to show a fall in quarterly revenue when it reports results on October 30 for the period ending January 1 0001 The Malines (mechelen) Antwerpen-based company is expected to report a 41.8% decrease in revenue to $69.796 million from $120.03 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
G

Basler AG, Greatland Gold, Sandvik AB

EUROPE RESEARCH ROUNDUP-Basler AG, Greatland Gold, Sandvik AB Oct 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Basler AG, Greatland Gold and Sandvik AB, on Tuesday. HIGHLIGHTS * Autoneum Holding AG AUTON.S : UBS raises PT to CHF 170 from CHF 160 * Azelis NV AZE.BR : HSBC raises to buy from hold * Basler AG BSLG.DE : Jefferies cuts to hold from buy * Greatland Gold Plc GGPL.L : Berenberg cuts to hold from buy * Sandvik AB SAND
A
B
E
F
G
I
I
N
P
R
S
S
S
T
R

U.S. Galapagos, Marsh & Mclennan, Travelers

U.S. RESEARCH ROUNDUP-Galapagos, Marsh & Mclennan, Travelers Oct 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Galapagos, Marsh & Mclennan and Travelers, on Tuesday. HIGHLIGHTS * Contineum Therapeutics Inc CTNM.O : Baird initiates coverage with outperform rating * Galapagos NV GLPG.O : JP Morgan cuts target price to $32 from $37 * Marsh & Mclennan MMC.N : KBW raises target price to $212 from $209 * Travelers TRV.
A
C
E
E
G
M
T
W
Z
A
F
T
L
P
U
W
P
S

Galapagos jumps after appointing EcoR1's Nodelman to its board

BUZZ-Galapagos jumps after appointing EcoR1's Nodelman to its board ** Shares in pharmaceutical company Galapagos GLPG.AS rise 4.3% after it appoints Oleg Nodelman, founder and portfolio manager of EcoR1 Capital, to its board of directors ** EcoR1 in August reported a 9.9% stake in Galapagos and said it planned to communicate with the management and the board about topics relating to co's performance and board composition ** "(Nodelman) will bring his track record in business development and cap
G

Galapagos Receives Transparency Notification From Ecor1 Capital

BRIEF-Galapagos Receives Transparency Notification From Ecor1 Capital Sept 16 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATION FROM ECOR1 CAPITAL Source text for Eikon: ID:nGNX1Q9lfM Further company coverage: GLPG.AS ( Reuters.Briefs@thomsonreuters.com )
G

Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19

BRIEF-Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19 Aug 23 (Reuters) - Galapagos NV GLPG.AS : ECOR1 CAPITAL LLC REPORTS 9.9% STAKE IN GALAPAGOS NV AS OF AUG 19 - SEC FILING ECOR1 CAPITAL LLC SAYS BELIEVES GALAPAGOS NV'S SECURITIES ARE DEEPLY "UNDERVALUED" ECOR1 CAPITAL LLC - INTENDS TO COMMUNICATE WITH GALAPAGOS’ MANAGEMENT, BOARD
G

U.S. STOCKS Workday, Roku, Dexcom

BUZZ-U.S. STOCKS ON THE MOVE-Workday, Roku, Dexcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's stock indexes jumped on Friday, with the benchmark S&P 500 index nearing a record high, after U.S. Federal Reserve Chair Jerome Powell said "the time has come" to reduce interest rates.
G
I
Q
L
R
U
U

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to open higher on Friday ahead of a speech from Federal Reserve Chair Jerome Powell that investors expect will offer hints on the pace of rate cuts in the world's biggest economy.
G
Q
R
U
E

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Friday with investors awaiting Federal Reserve Chair Jerome Powell's comments at the Jackson Hole Economic Symposium for clues on interest-rate cuts in the world's biggest economy.
G
R
U
E

Galapagos rises on FDA clearance for phase 1/2 1 study

BUZZ-Galapagos rises on FDA clearance for phase 1/2 ATALANTA-1 study ** Shares in Galapagos GLPG.AS rise 2.7%, paring earlier gains of as much as 4%, after the Belgian biotech company obtained FDA clearance to initiate its ATALANTA-1 study with GLPG5101 in the U.S. ** "We see the FDA clearance as an important milestone for Galapagos' GLPG5101 program," says KBC Securities, adding the company will now be able to start treating patients in the U.S.
G
K

Galapagos: FDA Clears IND Application For Phase 1/2 1 Study

BRIEF-Galapagos: FDA Clears IND Application For Phase 1/2 ATALANTA-1 Study Aug 23 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 ATALANTA-1 STUDY OF CD19 CAR-T, GLPG5101, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA Source text for Eikon: ID:nGNX1gGlDF Further company coverage: GLPG.AS (Gdansk N
G

Ashtead Group, Beazley, Entain

EUROPE RESEARCH ROUNDUP-Ashtead Group, Beazley, Entain Aug 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Group, Beazley and Entain, on Friday. HIGHLIGHTS * Ashtead Group Plc AHT.L : KeyBanc initiates coverage with sector weight rating * Beazley Plc BEZG.L : Berenberg raises target price to 950p from 880p * Entain Plc ENT.L : Deutsche Bank cuts target price to 958p from 1,089p * Rheinmetall AG RHMG.DE : Morgan Stanley up
A
A
A
A
B
B
B
C
C
D
D
E
G
G
H
H
H
I
K
O
B

U.S. STOCKS Morgan Stanley, Intel, Guardant

BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intel, Guardant Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq Composite was set to plunge into a correction on Friday, falling more than 10% from its July peak after weak employment numbers aggravated worries of a slowdown in the U.S.
A
B
C
C
G
I
J
M
M
N
Q
A
U
A
M
U
U
C
C

U.S. STOCKS Intel, Nvidia, Chevron

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Nvidia, Chevron Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were poised to slump at the open on Friday after weak employment numbers exacerbated worries of a slowdown in the U.S.
A
B
C
G
I
M
M
N
Q
A
U
A
U
C

U.S. STOCKS MercadoLibre, DoorDash, Coinbase

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, DoorDash, Coinbase Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Futures fell sharply on Friday after Amazon and Intel presented downbeat forecasts as concerns over the health of the U.S.
A
B
C
G
I
M
M
N
Q
A
A
U
B

Galapagos slips after it pauses drug candidate study

BUZZ-Galapagos slips after it pauses drug candidate study ** Shares in Galapagos GLPG.AS slide around 4% as the Belgian biotech company said it was temporarily pausing a drug candidate trial after one observed case of Parkinsonism ** The company said it would pause enrolment in the Phase 1/2 PAPILIO-1 for its drug candidate GLPG5301 in relapsed/ref
G

Galapagos NV reports results for the quarter ended in June - Earnings Summary

Galapagos NV reports results for the quarter ended in June - Earnings Summary Galapagos NV GLPG.AS reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 8 cents. The lone analyst forecast for the quarter was for a loss of 21 cents per share.
G

Galapagos Says FY Outlook Reaffirmed, Total Net Revenues For HY 140.3 Mln Euros

BRIEF-Galapagos Says FY Outlook Reaffirmed, Total Net Revenues For HY 140.3 Mln Euros Aug 1 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS NV: 2024 OUTLOOK REAFFIRMED: GALAPAGOS NV: TOTAL NET REVENUES FOR SIX MONTHS ENDED 30 JUNE 2024 AMOUNTED TO EUR 140.3 MILLION GALAPAGOS NV - HY OPERATING LOSS 71.3 MILLION EUROS VERSUS 27.7 MILLION EUROS Source te
G



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.